Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1:12:783057.
doi: 10.3389/fphar.2021.783057. eCollection 2021.

A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes

Affiliations

A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes

Yu Di et al. Front Pharmacol. .

Abstract

Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have become increasingly popular in the treatment of ocular diseases. However, few studies have determined the efficiency of unilateral intravitreal anti-VEGF injection in the fellow eye. Herein, we performed a study to investigate the drug concentration in fellow eyes and venous serum after unilateral intravitreal injection of conbercept into rabbit eyes. This is an experimental animal study. Thirty male New Zealand rabbits (60 eyes) were used. One eye of each rabbit was intravitreally injected with 0.5 mg of conbercept. Both eyes from six rabbits were enucleated on days 1, 3, 7, 14, and 30. Conbercept concentrations were measured in the serum, aqueous humor, and vitreous humor. We found conbercept was detected in the fellow eyes and serum of rabbits. Conbercept concentrations in the vitreous humor of the fellow eyes increased from 74.11 ng/ml on day 1 to 246.69 ng/ml on day 3 and then declined to 69.11 ng/ml after 30 days. The concentration in the aqueous humor peaked on day 1 with a concentration of 244.82 ng/ml and declined to 40.13 ng/ml after 30 days. The maximum conbercept concentrations in the aqueous humor and vitreous humor of fellow eyes were similar, which were 0.2 and 1.3% of those of the injected eye, respectively. A peak concentration of 102.49 ng/ml was achieved in the venous serum 1 day after intravitreal injection of conbercept, which was 0.08 and 0.5% of those of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the injected eye, respectively, and 41.5 and 41.8% of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the non-injected eye, respectively. In conclusion, after intravitreal injection of 0.5 mg of conbercept into rabbit eyes, very small amounts of conbercept were detected in the fellow non-injected eyes and venous serum.

Keywords: aqueous humor; conbercept; drug concentration; non-injected eyes; serum; vitreous.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Conbercept concentration in the vitreous humor and aqueous humor after intravitreal injection of 0.5 mg of conbercept. Samples were taken from the aqueous and vitreous of the injected eye.
FIGURE 2
FIGURE 2
Conbercept concentration in the vitreous humor, aqueous humor, and serum after intravitreal injection of 0.5 mg of conbercept. Samples were taken from the aqueous and vitreous of the non-injected eye.

Similar articles

Cited by

References

    1. Acharya N. R., Sittivarakul W., Qian Y., Hong K. C., Lee S. M. (2011). Bilateral Effect of Unilateral Ranibizumab in Patients with Uveitis-Related Macular Edema. Retina 31, 1871–1876. 10.1097/IAE.0b013e318213da43 - DOI - PubMed
    1. Avery R. L., Castellarin A. A., Steinle N. C., Dhoot D. S., Joseph Pieramici D., See R., et al. (2014). Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with Neovascular AMD. Br. J. Ophthalmol. 98, 1636–1641. 10.1136/bjophthalmol-2014-305252 - DOI - PMC - PubMed
    1. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Ezzat M. K., Singh R. J. (2007b). Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). Ophthalmology 114, 2179–2182. 10.1016/j.ophtha.2007.09.012 - DOI - PubMed
    1. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Singh R. J. (2007a). Pharmacokinetics of Intravitreal Bevacizumab (Avastin). Ophthalmology 114, 855–859. 10.1016/j.ophtha.2007.01.017 - DOI - PubMed
    1. Chen X., Li J., Li M., Zeng M., Li T., Xiao W., et al. (2013). KH902 Suppresses High Glucose-Induced Migration and Sprouting of Human Retinal Endothelial Cells by Blocking VEGF and PIGF. Diabetes Obes. Metab. 15, 224–233. 10.1111/dom.12008 - DOI - PubMed

LinkOut - more resources